ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, O'Neill K, Riggs M, et al. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci USA. 1990;87(12):4799–4803.
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203.
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21(9):1038–1047.
   PubMed Web of Science ®Google Scholar
• Azelby CM, Sakamoto MR, Bowles DW. ROS1 targeted therapies: current status. Curr Oncol Rep. 2021;23(8):94.
   PubMed Web of Science ®Google Scholar
• Feldman RA, Wang LH, Hanafusa H, et al. Avian sarcoma virus UR2 encodes a transforming protein which is associated with a unique protein kinase activity. J Virol. 1982;42(1):228–236.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol. 1986;6(8):3000–3004.
   PubMed Web of Science ®Google Scholar
• El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev. 2011;31(5):794–818.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Shibuya M. Tissue-specific expression of rat c-ros-1 gene and partial structural similarity of its predicted products with sev protein of Drosophila melanogaster. J Virol. 1990;64(5):2117–2125.
   PubMed Web of Science ®Google Scholar
• Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003;37(1):58–71.
   PubMed Web of Science ®Google Scholar
• Roskoski R. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res. 2017;121:202–212.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865–875.
   PubMed Web of Science ®Google Scholar
• Charest A, Lane K, McMahon K, et al. Association of a novel PDZ domain-containing peripheral golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J Biol Chem. 2001;276(31):29456–29465.
   PubMed Web of Science ®Google Scholar
• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from east asian never smokers. PLoS One. 2011;6(11):e28204.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou S-HI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870.
   PubMed Web of Science ®Google Scholar
• Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6(1):e15640.
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–4579.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381.
   PubMed Web of Science ®Google Scholar
• Charest A, Wilker EW, McLaughlin ME, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006;66(15):7473–7481.
   PubMed Web of Science ®Google Scholar
• Furcht CM, Muñoz Rojas AR, Nihalani D, et al. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene. 2013;32(18):2346–2355.
   PubMed Web of Science ®Google Scholar
• Jun HJ, Johnson H, Bronson RT, et al. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res. 2012;72(15):3764–3774.
   PubMed Web of Science ®Google Scholar
• Cao X, Chen XM, Xiao WZ, et al. ROS-mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC. Int J Mol Med. 2021;47(2):573–582.
   PubMed Web of Science ®Google Scholar
• Charest A, Kheifets V, Park J, et al. Oncogenic targeting of an activated tyrosine kinase to the golgi apparatus in a glioblastoma. Proc Natl Acad Sci USA. 2003;100(3):916–921.
   PubMed Web of Science ®Google Scholar
• Neel DS, Allegakoen DV, Olivas V, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 2019;79(3):546–556.
   PubMed Web of Science ®Google Scholar
• Mu FT, Callaghan JM, Steele-Mortimer O, et al. EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine “fingers” and contains a calmodulin-binding IQ motif. J Biol Chem. 1995;270(22):13503–13511.
   PubMed Web of Science ®Google Scholar
• Ahluwalia N, Bergeron JJ, Wada I, et al. The p88 molecular chaperone is identical to the endoplasmic reticulum membrane protein, calnexin. J Biol Chem. 1992;267(15):10914–10918.
   PubMed Web of Science ®Google Scholar
• Frangioni JV, Beahm PH, Shifrin V, et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992;68(3):545–560.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wu C, Ding W, et al. Prevalence of ROS1 fusion in chinese patients with non-small cell lung cancer. Thorac Cancer. 2019;10(1):47–53.
   PubMed Web of Science ®Google Scholar
• Cui M, Han Y, Li P, et al. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Mol Oncol. 2020;14(11):2787–2795.
   PubMed Web of Science ®Google Scholar
• Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22(11):2109–2119.
   PubMed Web of Science ®Google Scholar
• Xu Y, Chang H, Wu L, et al. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma. Exp Mol Pathol. 2020;117:104548.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-Small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Shaw AT. Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics? Oncologist. 2016;21(6):662–663.
   PubMed Web of Science ®Google Scholar
• Cao B, Wei P, Liu Z, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2016;9:131–138.
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Rossi G, Cozzolino I, et al. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. J Clin Pathol. 2020;73(2):96–101.
   PubMed Web of Science ®Google Scholar
• Viola P, Maurya M, Croud J, et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol. 2016;11(7):1029–1039.
   PubMed Web of Science ®Google Scholar
• Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–4457.
   PubMed Web of Science ®Google Scholar
• Hofman V, Rouquette I, Long-Mira E, et al. Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients. J Thorac Oncol. 2019;14(7):1204–1212.
   PubMed Web of Science ®Google Scholar
• Wang W, Cheng G, Zhang G, et al. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer. Lung Cancer. 2020;146:224–229.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013;37(9):1441–1449.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Smith D, Le CH, et al. Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization. Arch Pathol Lab Med. 2020;144(6):735–741. [Inserted FromOnline]
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489–503.
   PubMed Web of Science ®Google Scholar
• Capizzi E, Dall'Olio FG, Gruppioni E, et al. Clinical significance of ROS1 5' deletions in non-small cell lung cancer. Lung Cancer. 2019;135:88–91.
   PubMed Web of Science ®Google Scholar
• Clavé S, Rodon N, Pijuan L, et al. Next-generation sequencing for ALK and ROS1 rearrangement detection in patients with non-small-cell lung cancer: implications of FISH-positive patterns. Clin Lung Cancer. 2019;20(4):e421–e429.
   PubMed Web of Science ®Google Scholar
• Li W, Guo L, Liu Y, et al. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J Thorac Oncol. 2021;16(3):404–418.
   PubMed Web of Science ®Google Scholar
• Luk PP, Selinger CI, Mahar A, et al. Biomarkers for ALK and ROS1 in lung cancer: immunohistochemistry and fluorescent in situ hybridization. Arch Pathol Lab Med. 2018;142(8):922–928.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Zhao C, et al. High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer. Onco Targets Ther. 2019;12:3305–3311.
   PubMed Web of Science ®Google Scholar
• Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014;83(2):168–173.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Tsuta K, Wakai S, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol. 2014;27(5):711–720.
   PubMed Web of Science ®Google Scholar
• Boyle TA, Masago K, Ellison KE, et al. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015;16(2):106–111.
   PubMed Web of Science ®Google Scholar
• Bozzetti C, Nizzoli R, Tiseo M, et al. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagn Cytopathol. 2015;43(11):941–946.
   PubMed Web of Science ®Google Scholar
• Rossi G, Jocollé G, Conti A, et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl). 2017;8:45–55.
   PubMed Web of Science ®Google Scholar
• Reguart N, Teixidó C, Giménez-Capitán A, et al. Identification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients. Clin Chem. 2017;63(3):751–760.
   PubMed Web of Science ®Google Scholar
• Nong L, Zhang Z, Xiong Y, et al. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients. J Thorac Dis. 2019;11(12):4992–5003.
   PubMed Web of Science ®Google Scholar
• Guaitoli G, Bertolini F, Bettelli S, et al. Deepening the knowledge of rearrangements in non-small cell lung cancer: diagnosis, treatment, resistance and concomitant alterations. Int J Mol Sci. 2021;22(23):12867.
   PubMed Web of Science ®Google Scholar
• Shan L, Lian F, Guo L, et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One. 2015;10(3):e0120422.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Silva A, Zhang H, Jeffrey SS. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol. 2007;8:118.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 2013;24(1):59–66.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33(9):992–999.
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Hsieh M-S, Wu S-G, et al. Efficacy of Pemetrexed-Based chemotherapy in patients with ROS1 Fusion-Positive lung adenocarcinoma compared with in patients harboring other driver mutations in east asian populations. J Thorac Oncol. 2016;11(7):1140–1152.
   PubMed Web of Science ®Google Scholar
• Scheffler M, Schultheis A, Teixido C, et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget. 2015;6(12):10577–10585.
   PubMedGoogle Scholar
• Liang Y, Wakelee HA, Neal JW. Relationship of driver oncogenes to long-term pemetrexed response in non-small-cell lung cancer . Clin Lung Cancer. 2015;16(5):366–373.
   PubMed Web of Science ®Google Scholar
• Riess JW, Padda SK, Bangs CD, et al. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ROS1 gene rearrangements . Clin Lung Cancer. 2013;14(5):592–595.
   PubMed Web of Science ®Google Scholar
• Song Z, Su H, Zhang Y. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Cancer Med. 2016;5(10):2688–2693.
   PubMed Web of Science ®Google Scholar
• Ou SI, Zhu VW. CNS metastasis in ROS1+ NSCLC: an urgent call to action, to understand, and to overcome. Lung Cancer. 2019;130:201–207.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 Fusion-Positive Non-Small-Cell lung cancer. J Clin Oncol. 2021;39(11):1253–1263.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409.
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee J-S, et al. Open-Label, multicenter, phase II study of ceritinib in patients with Non-Small-Cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019;20(12):1691–1701.
   PubMed Web of Science ®Google Scholar
• Drilon A, Ou S-HI, Cho BC, et al. Repotrectinib (TPX-0005) is a Next-Generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK Solvent- front mutations. Cancer Discov. 2018;8(10):1227–1236.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SHI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Davare MA, Vellore NA, Wagner JP, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci USA. 2015;112(39):E5381–E5390.
   PubMed Web of Science ®Google Scholar
• Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4(2):156–164.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126.
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JCH, Kim DW, et al. Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411.
   PubMed Web of Science ®Google Scholar
• Michels S, Massutí B, Schildhaus HU, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-Rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol. 2019;14(7):1266–1276.
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30(12):1985–1991.
   PubMed Web of Science ®Google Scholar
• Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res. 2019;25(24):7312–7319.
   PubMed Web of Science ®Google Scholar
• Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of Central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717–1726.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15(4):628–639.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-Aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and Pan-Tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–3408.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):261–270.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–673.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929.
   PubMed Web of Science ®Google Scholar
• Nishio M, Felip E, Orlov S, et al. Final overall survival and other efficacy and safety results from ASCEND-3: phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC . J Thorac Oncol. 2020;15(4):609–617.
   PubMed Web of Science ®Google Scholar
• Crinò L, Ahn M-J, De Marinis F, et al. Multicenter phase II study of Whole-Body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873.
   PubMed Web of Science ®Google Scholar
• Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017;134:348–356.
   PubMed Web of Science ®Google Scholar
• Naito T, Shiraishi H, Fujiwara Y. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and Central nervous system metastases. Jpn J Clin Oncol. 2021;51(1):37–44.
   PubMed Web of Science ®Google Scholar
• Peled N, Gillis R, Kilickap S, et al. GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients. Lung Cancer. 2020;148:48–54.
   PubMed Web of Science ®Google Scholar
• Zhu VW, Lin YT, Kim DW, et al. An international Real-World analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. J Thorac Oncol. 2020;15(9):1484–1496.
   PubMed Web of Science ®Google Scholar
• Hochmair MJ, Fabikan H, Illini O, et al. Later-Line treatment with lorlatinib in - and -rearrangement-positive NSCLC: a retrospective, multicenter analysis. Pharmaceuticals (Basel). 2020;13(11):371.
   Google Scholar
• Hegde A, Hong DS, Behrang A, et al. Activity of brigatinib in crizotinib and ceritinib-resistant rearranged non-small-cell lung cancer. J Clin Oncol Precis Oncol. 2019;3(3):1–6.
   Google Scholar
• Dudnik E, Agbarya A, Grinberg R, et al. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. Clin Transl Oncol. 2020;22(12):2303–2311.
   PubMed Web of Science ®Google Scholar
• Zhang S, Anjum R, Squillace R, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527–5538.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2039.
   PubMed Web of Science ®Google Scholar
• Yun MR, Kim DH, Kim S-Y, et al. Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. Clin Cancer Res. 2020;26(13):3287–3295.
   PubMed Web of Science ®Google Scholar
• Cho BC, Doebele RC, Lin J, et al. Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK + advanced solid tumors. J Thorac Oncol. 2021;16(3):S174–S175.
   Google Scholar
• Nokihara H, Nishio M, Yamamoto N, et al. Phase 1 study of cabozantinib in japanese patients with expansion cohorts in non-small-cell lung cancer. Clin Lung Cancer. 2019;20(3):e317–e328.
   PubMed Web of Science ®Google Scholar
• Kato Y, Ninomiya K, Ohashi K, et al. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Cancer Sci. 2018;109(10):3149–3158.
   PubMed Web of Science ®Google Scholar
• Sun TY, Niu X, Chakraborty A, et al. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J Thorac Oncol. 2019;14(2):e21–e24.
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA, Vogelzang NJ, Kluger HM, et al. Results of a phase II placebo-controlled randomized discontinuation trial of cabozantinib in patients with non-small-cell lung carcinoma. Clinical Lung Cancer. 2019;20(2):74–81.e1.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Zhou JY, Yang N, et al. SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): results from the dose-finding portion in a single arm, first-in-human phase 1/2 study. J Clin Oncol. 2020;38(15):e21689–e21689.
   Google Scholar
• Xia ZJ, Ji YC, Sun DQ, et al. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. Acta Pharmacol Sin. 2021;42(6):998–1004.
   PubMed Web of Science ®Google Scholar
• Ma L, Xiao J, Guan Y, et al. SDK1-ALK fusion in a lung adenocarcinoma patient with excellent response to ALK inhibitor treatment: a case report. Front Oncol. 2022;12:860060.
   PubMed Web of Science ®Google Scholar
• Tafe LJ. Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets. Virchows Arch. 2017;471(2):155–164.
   PubMed Web of Science ®Google Scholar
• Kuwano M, Sonoda K, Murakami Y, et al. Overcoming drug resistance to receptor tyrosine kinase inhibitors: learning from lung cancer. Pharmacol Ther. 2016;161:97–110.
   PubMed Web of Science ®Google Scholar
• Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA. 2013;110(48):19519–19524.
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res. 2016;22(10):2351–2358.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Loriot Y, Kuo M-S, et al. Crizotinib-Resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-Rearranged lung cancers. Clin Cancer Res. 2016;22(24):5983–5991.
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in -positive non-small-cell lung cancer. J Clin Oncol Precis Oncol. 2017;2017(1):1–13.
   Google Scholar
• McCoach CE, Le AT, Gowan K, et al. Resistance mechanisms to targeted therapies in ROS1+ and ALK + non-small cell lung cancer. Clin Cancer Res. 2018;24(14):3334–3347.
   PubMed Web of Science ®Google Scholar
• Song A, Kim TM, Kim D-W, et al. Molecular changes associated with acquired resistance to crizotinib in ROS1-Rearranged Non-Small cell lung cancer. Clin Cancer Res. 2015;21(10):2379–2387.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Dziadziuszko R, Drilon A, et al. Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2. Ann Oncol. 2019;30:v865.
   Web of Science ®Google Scholar
• Zhou Y, Jiang W, Zeng L, et al. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. Lung Cancer. 2020;143:55–59.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Choudhury NJ, Yoda S, et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer . Clin Cancer Res. 2021;27(10):2899–2909.
   PubMed Web of Science ®Google Scholar
• Gou W, Zhou X, Liu Z, et al. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. Cancer Lett. 2018;422:19–28.
   PubMed Web of Science ®Google Scholar
• Roupakia E, Chavdoula E, Karpathiou G, et al. Canonical NF-κB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-Mesenchymal cell transition. Cancers (Basel). 2021;13(17):4302.
   PubMed Web of Science ®Google Scholar
• Ku BM, Bae YH, Lee KY, et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest New Drugs. 2020;38(2):360–368.
   PubMed Web of Science ®Google Scholar
• Cargnelutti M, Corso S, Pergolizzi M, et al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget. 2015;6(7):5182–5194.
   PubMed Web of Science ®Google Scholar
• Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013;8(12):e82236.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Le AT, Wrona A, et al. An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer. J Thorac Oncol. 2016;11(8):1273–1281.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Nagy RJ, et al. Molecular analysis of plasma from patients with ROS1-Positive NSCLC. J Thorac Oncol. 2019;14(5):816–824.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–e172.
   PubMed Web of Science ®Google Scholar
• Lee J-K, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into Small-Cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35(26):3065–3074.
   PubMed Web of Science ®Google Scholar
• Balla A, Khan F, Hampel KJ, et al. Small-cell transformation of -rearranged non-small-cell adenocarcinoma of the lung. Cold Spring Harb Mol Case Stud. 2018;4(2):a002394.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Langenbucher A, Gupta P, et al. Small cell transformation of fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020;4:21.
   PubMed Web of Science ®Google Scholar